Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: A case report and review of the literature

Rupa R. Patel, Rachel Presti, Laura C. Harrison, William G. Powderly, Philip A. Chan

Research output: Contribution to journalArticlepeer-review

Abstract

Pre-exposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF), can effectively prevent HIV acquisition. However, TDF can cause changes in bone mineral density (BMD). There is little information on the use of PrEP among patients with bone disease. We present a case report of a female with pre-existing osteoporosis who was prescribed PrEP. Over the course of 9 months of consistent PrEP use, verified by dried blood spot testing, we report a lack of BMD changes on serial dual-emission X-ray absorptiometry scans in this patient. This case can inform PrEP care for patients with pre-existing bone disease.

Original languageEnglish
Pages (from-to)379-382
Number of pages4
JournalAntiviral Therapy
Volume23
Issue number4
DOIs
StatePublished - 2018

Fingerprint

Dive into the research topics of 'Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: A case report and review of the literature'. Together they form a unique fingerprint.

Cite this